Zhejiang Hisun Pharmaceutical (600267.SH) releases a forecasted profit, estimating a net profit of 570-630 million yuan in 2024, turning losses into profits.
Guangzhou Pharmaceuticals Corporation (stock code: 600267.SH) announced that the company is expected to achieve attributable net profit to shareholders of the listed company for the year 2024...
Zhejiang Hisun Pharmaceutical (600267.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 570 million to 630 million yuan in 2024, compared to a loss in the same period last year.
Related Articles
Xinhua Winshare Publishing & Media (00811) signed a Procurement Contract with the Sichuan Provincial Student Financial Assistance Management Center, a public institution directly under the Sichuan Provincial Department of Education.
Shanghai RAAS Blood Products (002252.SZ): "SR604 Injection" enters Phase III clinical trials
China Harzone Industry Corp. (300527.SZ) plans to apply to the Shenzhen Stock Exchange for the removal of the other risk warning on its stock trading.
Xinhua Winshare Publishing & Media (00811) signed a Procurement Contract with the Sichuan Provincial Student Financial Assistance Management Center, a public institution directly under the Sichuan Provincial Department of Education.
Shanghai RAAS Blood Products (002252.SZ): "SR604 Injection" enters Phase III clinical trials
China Harzone Industry Corp. (300527.SZ) plans to apply to the Shenzhen Stock Exchange for the removal of the other risk warning on its stock trading.
RECOMMEND
